477 related articles for article (PubMed ID: 26051802)
1. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Fiano R; Orio PF; Adamovich E
Brachytherapy; 2015; 14(5):677-85. PubMed ID: 26051802
[TBL] [Abstract][Full Text] [Related]
2. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial.
Merrick GS; Wallner KE; Butler WM; Galbreath RW; Taira AV; Orio P; Adamovich E
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e449-55. PubMed ID: 22196131
[TBL] [Abstract][Full Text] [Related]
3. Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease?
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Adamovich E
Brachytherapy; 2016; 15(1):79-84. PubMed ID: 26525214
[TBL] [Abstract][Full Text] [Related]
4. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
5. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
6. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
Wallner K; Merrick G; True L; Sherertz T; Sutlief S; Cavanagh W; Butler W
Radiother Oncol; 2005 Jun; 75(3):307-10. PubMed ID: 16086912
[TBL] [Abstract][Full Text] [Related]
7. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
8. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
9. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
10. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials.
Ghaly M; Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1288-93. PubMed ID: 12654439
[TBL] [Abstract][Full Text] [Related]
11. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
12. Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation.
Stone NN; Skouteris V; Stock RG
Brachytherapy; 2020; 19(3):275-281. PubMed ID: 32217039
[TBL] [Abstract][Full Text] [Related]
13. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
[TBL] [Abstract][Full Text] [Related]
14. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation.
Orio P; Wallner K; Merrick G; Herstein A; Mitsuyama P; Thornton K; Butler W; Sutlief S
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):342-6. PubMed ID: 17236959
[TBL] [Abstract][Full Text] [Related]
16. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
Brachman DG; Thomas T; Hilbe J; Beyer DC
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):111-7. PubMed ID: 10924979
[TBL] [Abstract][Full Text] [Related]
17. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis.
Coen JJ; Zietman AL; Rossi CJ; Grocela JA; Efstathiou JA; Yan Y; Shipley WU
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e25-31. PubMed ID: 21470787
[TBL] [Abstract][Full Text] [Related]
18. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
19. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
Fang LC; Dattoli M; Taira A; True L; Sorace R; Wallner K
Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapy.
Sherertz T; Wallner K; Merrick G; Cavanagh W; Butler W; Reed D; True L
Cancer J; 2004; 10(5):301-6. PubMed ID: 15530259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
